SLN Silence Therapeutics Plc ADRs
Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom. This is an ADR of a company whose stock trades outside of the U.S. as the symbol LN:SLN.
$8.88 -0.31 (-3.37%)
As of 03/27/2023 11:04:19 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: United Kingdom
Country of incorporation:
IPO date: 09/08/2020
Outstanding shares: 29,928,240
Average volume: 65,024
Market cap: $269,054,878
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol: B9GTXM6
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%